NDR White Paper Issue 23: Horses to Humans thymopentin has value
Levamisole and thymopentin, the link in treating ALS
top of page
NDR White Papers
-
- Jun 29, 2022
- 4 min
NDR White Paper Issue 21: Peptide Array Technology Provides a Cornerstone for ALS Research
Microarray technology using ALS-associated peptides
25
-
- Jun 9, 2022
- 1 min
Bionox
The thymus gland is a specialized organ of the immune system. In the past the thymus was viewed as more or less an unnecessary organ....
27
-
- Jun 6, 2022
- 4 min
NDR White Paper Issue 20: Can Elamipretide target mitochondrial dysfunction in ALS?
Amyotrophic lateral sclerosis (ALS) is associated with mitochondrial dysfunction and weight loss. Mitochondria are the powerhouse of the...
23
-
- May 27, 2022
- 3 min
White Paper Issue 19: NDRs miRNA project
ALS is thought to be a multistep disease process that involves a complex interplay between inherited genes indicating the level of risk...
20
-
- May 23, 2022
- 9 min
White Paper Issue 18: Bringing Patients to Treatments
Patient frustration with the lack of ALS treatment options and the progression of compounds through the drug delivery pipeline is evident...
32
-
- Apr 6, 2022
- 3 min
White Paper Issue 17: Effectiveness of levamisole HCl and thymalfasin in two mouse models of ALS
Levamisole HCl and Zadaxin tested in two mouse models of ALS
33
NDR
- Mar 31, 2022
- 4 min
White Paper Issue 16: Seeing ALS
Could optical coherence tomography be useful in stratifying ALS patients? Ocular nerves are specialized connections to the central...
13
NDR
- Mar 27, 2022
- 4 min
White Paper Issue 15: Are in vitro Neuronal Cells Models for ALS discovery?
in vitro neuronal cells considered for ALS drug discovery
21
NDR
- Mar 2, 2022
- 6 min
White Paper Issue 14: Utility to Futility: Zilucoplan fails in human ALS trial
Thomas Edison famously said, “I haven’t failed—I’ve just found 10,000 that won’t work.” Unfortunately, that is the state of the art for...
87
NDR
- Feb 17, 2022
- 3 min
White Paper Issue 13: NDR’s Roadmap to an ALS Cure
Finding a cure for ALS is a lofty goal shared by all those involved in the field. The differences between the organizations that support...
38
NDR
- Jan 10, 2022
- 3 min
NDR White Paper Issue 11: Mechanisms of common pathologies in ALS
Despite the initial cause, all cases of ALS, familial or sporadic, follow a final common pathogenesis. The ability for the body to...
36
NDR
- Jan 7, 2022
- 4 min
NDR White Paper Issue 10: Genetics and ALS
In Ancient Egypt a person’s essence or soul was passed to their descendants, symbolized by Ka. Amyotrophic lateral sclerosis (ALS) has...
16
NDR
- Jan 5, 2021
- 1 min
White Paper Issue 9: Stress Response in ALS: Dr. Robert Naviaux
Research in our lab has led to a new understanding of the ancient biology that underlies the circle of injury and recovery. New medicines...
31
NDR
- Dec 26, 2020
- 4 min
NDR White Paper Issue 8: ALS and epigenetics
Nothing illustrates that change is the essence of life quite like the butterfly. How does this cloudless sulphur caterpillar, eating the...
30
NDR
- Nov 20, 2020
- 7 min
NDR White Paper Issue 7: Models of ALS
Cathleen Lutz (Jackson Laboratory) described ALS as a “complex disease and consists of a group of conditions unified by a common theme,...
32
NDR
- Nov 5, 2020
- 4 min
NDR White Paper Issue 6: Energy Metabolism
NDR is approaching ALS from multiple directions- in 2021 we have 17 active projects! What is fascinating is the emerging overlap between...
22
NDR
- Aug 28, 2020
- 3 min
NDR White Paper Issue 5: Activity of Thymosan
Immunonormalizing molecules thymopoietin and levamisole HCl Inflammation and regulation of inflammatory responses are necessary for life....
49
NDR
- Aug 4, 2020
- 4 min
NDR White Paper Issue 4: C9orf72
RAN Proteins The discovery of a repeat expansion1 in the C9orf72 gene is important because it is a model to explain central...
15
NDR
- May 15, 2020
- 3 min
NDR White Paper Issue 3: Adipose & Secretome
The role of fat cells in treatment of ALS Amyotrophic lateral sclerosis is a (heterogeneous) neurodegenerative disorder with a variable...
17
NDR
- May 7, 2020
- 4 min
NDR White Paper Issue 2: Treatments Are Lacking
NDR’s goals are simple, bring promising therapies to ALS patients and know which treatment is appropriate for a patient by evaluating...
20
NDR
- May 1, 2020
- 3 min
NDR White Paper Issue 1: Thymopoietin
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease of animals and man with life-altering consequences. The defining pathology...
52
bottom of page